AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

Clin Infect Dis. 2020 Aug 9;ciaa1176. doi: 10.1093/cid/ciaa1176. Online ahead of print.


In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.

Keywords: AVIFAVIR; COVID-19; SARS-CoV-2; favipiravir.